RecruitingPhase 1Phase 2NCT06209580

AMT-253 in Patients With Advanced Solid Tumours

Phase I/II Study of AMT-253 in Patients With Unresectable or Metastatic Malignant Melanoma and Other Advanced Solid Tumors

Sponsor

Multitude Therapeutics Inc.

Enrollment

96 participants

Start Date

Jan 31, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors Malignant Melanoma

Summary

This is a non-randomized, open-label, multicenter Phase I/II study of AMT-253 in patients with Unresectable or Metastatic Malignant Melanoma and other Advanced Solid Tumors. This study include phase I dose escalation and phase II dose expansion.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new drug called AMT-253 in patients with advanced solid tumors (including melanoma) that have stopped responding to standard treatments. It aims to find a safe dose and see early signs of whether the drug shrinks tumors. **You may be eligible if...** - You have confirmed advanced melanoma or another solid tumor - Your cancer has progressed during or after at least one prior treatment - No further standard treatment options are available or suitable for you - You have at least one measurable tumor that can be tracked **You may NOT be eligible if...** - Your cancer has spread to the brain in an active, uncontrolled way - You have serious heart, liver, or kidney problems - You have received treatments that would interfere with this drug Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.